Erythropoietin. Biology and clinical applications

Tabbara, Imad A.

doi:10.1001/archinte.153.3.298

Cited by 15 publications

(5 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Like growth hormone(GH), it is also a member of the hematopoietic super family which consists of GH, EPO, granulocyte and macrophage colony-stimulating factor, interleukin 3 [IL-3], IL-4, IL-6, IL-7. All of them have similarities in their receptor structure [16,17]. It is likely that cross-reactivity between certain growth factors may exist.…”

Section: Discussionmentioning

confidence: 99%

The effect of erythropoietin on healing of obstructive vs nonobstructive left colonic anastomosis: an experimental study

et al. 2007

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

The effect of erythropoietin on healing of obstructive vs nonobstructive left colonic anastomosis: an experimental study

et al. 2007

View full text Add to dashboard Cite

show abstract

“…The use of rHuEPO in pregnancy has been limited by the fear of possible direct or indirect fetal repercussions. Transplacentar passage of rHuEPO would theoretically carry the risk of polycythemia, while maternal hypertension and seizures, attributable to rHuEPO, would be difficult to distinguish from preeclampsideclampsia and could indirectly affect the fetus ( 1 ).…”

Section: Discussionmentioning

confidence: 99%

“…Doses of 1000 to 2000 U of rHuEPO were administrated each two or three days, resulting in a total weekly dose of 50 to 100 U/Kg, which is a relatively low dose and therefore related to a lower incidence of side effects (1). Subcutaneous administration, which has proved to be the most efficient, was chosen (1 2).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Maternal and Perinatal Implications of the Use of Human Recombinant Erythropoietin

Braga

Marques

Branco

et al. 1997

Obstetrical & Gynecological Survey

View full text Add to dashboard Cite

Background. The use of human recombinant erythropoietin (rHuEPO) in pregnant patients has been limited by the fear of eventual maternal and fetal repercussions (either direct or indirect). Methods. The authors present their experience with the use of rHuEPO during pregnancy, with two pregnant women with kidney transplants and in three others with chronic renal insufficiency (one with diabetic nephropathy, another dialysis dependent), all with hematocrit below 30% and adequate iron reserves. Results. Three of the patients had needed blood transfusions before beginning therapy, and another needed transfusion after significant metrorrhagia. The length of the treatment varied between 2 and 23 weeks and the hematocrit at delivery varied between 26% and 36%. Secondary effects (appearance or worsening of hypertension and seizures) were nil. There was one fetal death at 23 weeks of pregnancy (following an abruptio placentce), two neonates weighing between the 5th and the 10th percentiles, and three needing phototherapy (1 to 2 days). One year after birth, all showed a normal ponderal and neurologic development.Conclusions. Among the cases presented, no maternal and perinatal complications attributable to rHuEPO were registered. It is important that institutions report their experiences with the use of rHuEPO, given its restrictive indications and the limited experience of each institution.

show abstract

“…EPO production is regulated by the relative oxygen tension of the cells involved in its synthesis [1,2]. Therefore, hypoxia, anemia, and cardiovascular insufficiency enhance its production [3].…”

Section: Introductionmentioning

confidence: 99%